Net Income

Rezolute's stock plummets after its lead drug fails a key trial, raising questions about its future and highlighting the brutal realities of biotech.

With a new board chair and a clear shareholder mandate, Edgewater Wireless is shifting from R&D to monetizing its game-changing Spectrum Slicing tech.

By replacing spreadsheets with a cloud platform, New Mexico created a 4.25x funding multiplier, setting a new standard for government efficiency.

A single crypto campaign generates $53.5B in futures volume. We dissect MEXC's strategy and what it reveals about the exchange wars and token adoption.

A landmark UK study reveals an AI diagnostic tool that predicts heart attacks with stunning accuracy and offers a £25 million lifeline to strained health budgets.

Bill Ackman's fund posted a stellar 24.1% return. We dive into the high-conviction plays and innovative structure driving this market-beating performance.

A new rapid saliva test from ImpetusDX promises to revolutionize oral care by linking gum health to systemic disease, but can it overcome market hurdles?

A new contract for TGS in Brazil signals enduring appeal for offshore oil. Discover how 4D seismic is unlocking value in mature, complex energy fields.

BW LPG declared a solid dividend, yet its stock fell. We dissect the numbers, peer strategies, and market forces to see what this reveals about the shipping giant.

The industrial giant secured a rare dual 'A' rating from CDP. We decode what this means for its strategy, competitors, and ESG-focused investors.

With two key drug approvals, Sanofi isn't just treating rare diseases in China; it's executing a playbook that redefines market entry and dominance.

A rival bid reshaped a major gold merger, creating a West African powerhouse. Here’s how the deal was saved and what it means for the market.

Stewart Information Services is raising millions via a stock offering. We analyze the strategy, the market signals, and the impact on shareholder value.

Glance is partnering with IAS to bring ad verification to 250M+ users in India and Indonesia, a strategic move to combat fraud and lure premium brands.

The return of a pharma-finance veteran to MediPharm's board isn't just a personnel change; it's a strategic move to secure its global pharmaceutical ambitions.

Natera's Signatera test salvaged key insights from a failed clinical trial, creating a new roadmap for personalized breast cancer treatment and logistics.

After major setbacks, a surge of innovative drugs is set to transform the ALS market. We decode the science, the money, and what it means for patients.

NREF's massive capital raise signals strong investor confidence. We dive into what this bold move reveals about the market and income-seeking investors.

Serve Robotics and Uber Eats launch sidewalk robots in Alexandria, Va., testing the scalability, economics, and public acceptance of last-mile automation.

Serina Therapeutics has answered the FDA's challenge. A 30-day clock now ticks on its novel Parkinson's therapy and its disruptive drug delivery platform.